Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR C797S/T790M/del19 (#RDB15492)

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.

Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, C797S, T790M, and deletion in exon 19, EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.
Comment cDNA was obtained from HCC-827 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
備考
Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15492 pENTER-EGFR C797S/T790M/del19 DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pENTER-EGFR C797S/T790M/del19 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15492).

Reference section:

Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15492_A7K8p1-1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 (Pr0531)
Region: rrnB T1 ter, attL1, insert 5'
Sequence file: RDB15492_A7K8a.seq check
>D04925A5_A7K8_2_rrnBT1ter_F2_E04_13_ABI24.ab1
    1 AGCAGATCTT CGACTGAGCC TTTCGTTTTA TTTGATGCCT GGCAGTTCCC TACTCTCGCG
   61 TTAACGCTAG CATGGATGTT TTCCCAGTCA CGACGTTGTA AAACGACGGC CAGTCTTAAG
  121 CTCGGGCCCC AAATAATGAT TTTATTTTGA CTGATAGTGA CCTGTTCGTT GCAACAAATT
  181 GATGAGCAAT GCTTTTTTAT AATGCCAACT TTGTACAAAA AAGCAGGCTC CGCGGCCGCC
  241 CCCTTCACCA TGCGACCCTC CGGGACGGCC GGGGCAGCGC TCCTGGCGCT GCTGGCTGCG
  301 CTCTGCCCGG CGAGTCGGGC TCTGGAGGAA AAGAAAGTTT GCCAAGGCAC GAGTAACAAG
  361 CTCACGCAGT TGGGCACTTT TGAAGATCAT TTTCTCAGCC TCCAGAGGAT GTTCAATAAC
  421 TGTGAGGTGG TCCTTGGGAA TTTGGAAATT ACCTATGTGC AGAGGAATTA TGATCTTTCC
  481 TTCTTAAAGA CCATCCAGGA GGTGGCTGGT TATGTCCTCA TTGCCCTCAA CACAGTGGAG
  541 CGAATTCCTT TGGAAAACCT GCAGATCATC AGAGGAAATA TGTACTACGA AAATTCCTAT
  601 GCCTTAGCAG TCTTATCTAA CTATGATGCA AATAAAACCG GACTGAAGGA GCTGCCCATG
  661 AGAAATTTAC AGGAAATCCT GCATGGCGCC GTGCGGTTCA GCAACAACCC TGCCCTGTGC
  721 AATGTGGAGA GCATCCAGTG GCGGGACATA GTCAGCAGTG ACTTTCTCAG CAACATGTCG
  781 ATGGACTTCC AGAACCACCT GGGCAGCTGC CAAAAGTGTG ATCCAAGCTG TCCCAATGGG
  841 AGCTGCTGGG GTGCAGGAGA GGAGAACTGC CAGAAACTGA CCAAAATCAT CTGTGCCCAG
  901 CAGTGCTCCG GGCGCTGCCG TGGCAAGTCC CCCCAGTGAC TGCTGCCACA ACCAGTGTGC
  961 TGCAGCTGCA CAGGGCCCCC GGGAGAGCGA CTGCCCTGGT CTGCCGCAAA TTCCCGAGAC
 1021 GAAGCCACGT GCAAAGGACA CCTGCCCCCC CCACTTCATG CTTCTTACAA CCCCCACCAC
1081 GTTAACCAGA TGATGTGAAC CCCGAGGTCA AAATAACAGG CCTTTTGGGA AGC
//
Primer: pDONR_R (Pr0071)
Region: attL2, insert 3'
Sequence file: RDB15492_A7K8b.seq check
>D04925A5_A7K8_2_pDONR_R_E08_14_ABI24.ab1
    1 GGCGGACGGC AGGACGCTAT GACCATGTAA TACGACTCAC TATAGGGGAT ATCAGCTGGA
   61 TGGCAAATAA TGATTTTATT TTGACTGATA GTGACCTGTT CGTTGCAACA AATTGATAAG
  121 CAATGCTTTC TTATAATGCC AACTTTGTAC AAGAAAGCTG GGTCGGCGCG CCCACCCTTT
  181 CATGCTCCAA TAAATTCACT GCTTTGTGGC GCGACCCTTA GGTATTCTGC ATTTTCAGCT
  241 GTGGAGCCCT TAAAGATGCC ATTTGGCTTG GCTTCCTTGG GAAAGAAGTC CTGCTGGTAG
  301 TCAGGGTTGT CCAGGCTAAT TTGGTGGCTG CCTTTCTGGG CCCAGTGGGC AGGGCTGTCG
  361 AATGTGCTGT TGACACAGGT GGGCTGGACA GTGTTGAGAT ACTCGGGGTT GCCCACTGCA
  421 GTGCTGTGGG GGTCCTGGTA GTGTGGGTCT CTGCTGGGCG CGGGGTTCAG AGGCTGATTG
  481 TGATAGACAG GATTCTGCAC AGAGCCAGCG GGCCTTTTGG GAACGGACTG GTTTATGTAT
  541 TCAGGCACTG GGAGGAAGGT GTCGTCTATG CTGTCCTCAG TCAAGGCGCC TGTGGGGTCT
  601 GAGCTGTATC GCTGCAAGAA GCTGTCTTCC TTGATGGGAC AGCTTTGCAG CCCATTTCTA
  661 TCAATGCAAG CCACGGTGGA ATTGTTGCTG GTTGCACTCA GAGAGCTCAG GAGGGGAGTC
  721 CGTGACGTGG AGGGGCTGCT GAAGAAGCCC TGCTGTGGGA TGAGGTACTC GTCGGCATCC
  781 ACCACGTCGT CCATGTCTTC TTCATCCATC AGGGCACGGT AGAAGTTGGA GTCTGTAGGA
  841 CTTGGCAAAT GCATTCTTTC ATCCCCCTGA ATGACAAGGT AGCGCTGGGG GGTCTCGGGC
  901 CATTTTGGAG AATTCGATGA TCAACTCACG GAACTTTGGG CGACTATCTG CGTCTATCAT
  961 CCAGCACTTG ACCATGATCA TGTAGACATC GATGGTACAT ATGGGTGGCT GAGGAGGGCG
 1021 TTTCTCCTTT CTCCAGGATG GAGGAGATTC TCGGCTGGGC AGGATTCCCG TCATATGACT
1081 GGAATTCTAA AGGTCAATCC AACTTCCCAA AACCG
//
Primer: EGFR-F5 (Pr0313)
Region: insert middle region (C797S, T790M, del19)
Sequence file: RDB15492_A7K8c.seq check
>D04925A5_A7K8_2_EGFR-F5_E09_15_ABI24.ab1
    1 AACATTAATC CGTCATCGCC ACTGGGATGG TGGGGGCCCT CCTCTTGCTG CTGGTGGTGG
   61 CCCTGGGGAT CGGCCTCTTC ATGCGAAGGC GCCACATCGT TCGGAAGCGC ACGCTGCGGA
  121 GGCTGCTGCA GGAGAGGGAG CTTGTGGAGC CTCTTACACC CAGTGGAGAA GCTCCCAACC
  181 AAGCTCTCTT GAGGATCTTG AAGGAAACTG AATTCAAAAA GATCAAAGTG CTGGGCTCCG
  241 GTGCGTTCGG CACGGTGTAT AAGGGACTCT GGATCCCAGA AGGTGAGAAA GTTAAAATTC
  301 CCGTCGCTAT CAAGACATCT CCGAAAGCCA ACAAGGAAAT CCTCGATGAA GCCTACGTGA
  361 TGGCCAGCGT GGACAACCCC CACGTGTGCC GCCTGCTGGG CATCTGCCTC ACCTCCACCG
  421 TGCAGCTCAT CATGCAGCTC ATGCCCTTCG GCTCCCTCCT GGACTATGTC CGGGAACACA
  481 AAGACAATAT TGGCTCCCAG TACCTGCTCA ACTGGTGTGT GCAGATCGCA AAGGGCATGA
  541 ACTACTTGGA GGACCGTCGC TTGGTGCACC GCGACCTGGC AGCCAGGAAC GTACTGGTGA
  601 AAACACCGCA GCATGTCAAG ATCACAGATT TTGGGCTGGC CAAACTGCTG GGTGCGGAAG
  661 AGAAAGAATA CCATGCAGAA GGAGGCAAAG TGCCTATCAA GTGGATGGCA TTGGAATCAA
  721 TTTTACACAG AATCTATACC CACCAGAGTG ATGTCTGGAG CTACGGGGTG ACCGTTTGGG
  781 AGTTGATGAC CTTTGGATCC AAGCCATATG ACGGAATCCC TGCCAGCGAG ATCTCCTCCA
  841 TCCTGGAGAA AGGAGAACGC CTCCCTCAGC CACCCATATG TACCATCGAT GTCTACATGA
  901 TCATGGTCAA GTGCTGGATG ATAGACGCAG ATAGTCGCCC AAAGTTTCCG TGAGTTGATC
  961 ATCGAATTCT CCCAAAATGG CCCGAGACCC CCAGCGCTAC CCTTTGTCAT TCAGGGGGAT
 1021 GAAAGATGCA TTTGCCAGTC CCTACAGGAC TCTACTTCTA CGTGCCCTGA TGTATGAAGA
1081 AGACATCACG GAACGTCTTG GAATGCT
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]